Document:

Unassociated Document

    
      Settlement
agreement between Biophan Technologies Inc., Biophan Europe GmbH, Tomovation
GmbH and Andreas Melzer

      

      In order
to settle all disputes and claims between the parties, the parties herewith
agree as follows without acknowledging any legal obligation
thereto:

      

      
        	
                1.

              	
                The
      parties agree that the settlement payment of US $ 80,000.00 and the grant
      of 150,000 shares of Biophan Inc. stock which Biophan Inc
      promised to pay to Michael Friebe on behalf of Biophan Europe (covering
      all reciprocal claims between Michael Friebe and Biophan Europe) under the
      settlement agreement with him as of 17 April / 24 April / 5 May 2008 are
      set off against any capital contribution to be paid by Biophan Inc. to
      Biophan Europe (as stipulated in Section 1.4 of the Share Purchase
      Agreement between Biophan Inc.– aMRIs GmbH (now Biophan Europe) and others
      of February 24, 2005 (SPA)).

              

      

      

      
        	
                2.

              	
                Biophan
      Inc agrees to sell shares in Biophan Europe in the nominal amount of EUR
      7.750,00 to Andreas Melzer (31 % of all shares) for a sum of EUR 1,00. The
      provision in this clause is conditional to the execution of a formal
      notarized agreement.

              

      

      

      
        	
                3.

              	
                Biophan
      Inc. agrees to pay to Tomovation on behalf of Biophan Europe a total sum
      of US $ 29,300.00 in cash, of which $10,000.00 is to cover legal fees and
      $ 19,300.00 to cover all reciprocal claims between Tomovation and Biophan
      Europe and vice versa, and to grant to Tomovation 150.000 shares of
      Biophan Inc. stock.
      The parties agree that this payment and the grant of shares are set
      off against any capital contribution to be paid by Biophan Inc. to Biophan
      Europe (as stipulated in Section 1.4 of the Share Purchase Agreement
      between Biophan Inc.– aMRIs GmbH (now Biophan Europe) and others of
      February 24, 2005 (SPA)).

              

      

      

      
        	
                4.

              	
                After
      receipt of payment of the above mentioned sum of US $ 29,300.00 Tomovation
      will withdraw its action in the pending law suit between Tomovation and
      Biophan Europe before the Landgericht Dortmund Aktz.: 18 O 45/07. Each
      party bears its own costs. Biophan Europe waives its right to ask for a
      decision acc. to § 269 III ZPO (German Law of Proceedings) on the
      proceedings ́ costs.

              

      

      

      
        	
                5.

              	
                Tomovation
      agrees to sell its shares in Biophan Europe for a sum of EUR 1.00 to
      Andreas Melzer. The provision in this clause is conditional to the
      execution of a formal notarized
agreement.

              

      

      

      
        	
                6.

              	
                Biophan
      Inc. and Biophan Europe each releases all claims against Tomovation and
      Tomovation releases all claims against each of Biophan Inc. and Biophan
      Europe. If this mutual release constitutes a waiver of claims the parties
      herewith agree to any such waiver.

              

      

      

      
        	
                7.

              	
                Biophan
      Inc. and Biophan Europe mutually release all claims between each other as
      accumulated or asserted per today. If this mutual release constitutes a
      waiver of claims the parties herewith agree to any such
    waiver

              

      

      

      
        	
                8.

              	
                Biophan
      Inc. and Andreas Melzer mutually release all claims between each other as
      accumulated or asserted per today.  If this mutual release
      constitutes a waiver of claims the parties herewith agree to any such
      waiver.

              

      

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      2

       

      
        	
                9.

              	
                The
      parties agree to merge the two entities, Biophan Europe and aMRIs Patente
      Verwaltungs GmbH & Co. KG into a Newco in order to consolidate the
      operating entity with the patent holding entity. Andreas Melzer as CEO of
      Biophan Europe is herewith authorized to take all necessary steps to
      prepare the merger. The provision in this clause is conditional to the
      execution of formal notarized merger
agreements.

              

      

      

      
        	
                10.

              	
                The
      parties agree on the settlement of open claims and the future
      funding/financing of Biophan Europe as
follows:

              

      

      

      
        	
              	
                a)

              	
                Biophan
      Europe is entitled to sell its 58.4% interest in MR:Comp and to retain all
      proceeds from the sale, which has already been undertaken on April 22,
      2008.

              

      

      

      
        	
              	
                b)

              	
                Biophan
      Inc. agrees to pay to Biophan Europe a sum of US $ 91,000.00. This payment is part
      of the capital contribution under article 1.4 of the Share Purchase
      Agreement between Biophan Inc.– aMRIs GmbH (now Biophan Europe) and others
      of February 24, 2005 (SPA).

              

      

      

      
        	
              	
                c)

              	
                On
      the date hereof the parties will sign an Agreement of Mutual Releases and
      Waivers with respect to the Share Purchase Agreement among Biophan Inc.–
      aMRIs GmbH (now Biophan Europe) and others of February 24, 2005 (SPA)
      whereby the parties, subject to the terms and conditions of this
      Settlement Agreement, settle all claims between each other related to the
      SPA.

              

      

      

      
        	
              	
                d)

              	
                Biophan
      Inc. will assist Biophan Europe in the search for independent
      capitalization of Biophan Europe from third parties either as loan or as
      equity.

              

      

      

      
        	
                11.

              	
                The
      parties agree that this Settlement Agreement and the following Settlement
      Agreement between Biophan Technologies Inc., aMRIs Patente VerwaltungsGmbH
      & Co. KG (AMP), AMRIS Patente GmbH (AMRIS), Tomovation
      GmbH and Michael Friebe shall simultaneously become valid and binding upon
      the respective parties upon
signing.

              

      

      

      
        	
                12.

              	
                This
      Settlement Agreement supersedes and replaces all previous settlement
      agreements between the parties relating to the subject matter of this
      Settlement Agreement, except for the Settlement Agreement with Biophan
      Inc., Biophan Europe and Michael Friebe as of 17 April / 24 April / 5 May
      2008 which remains in force.

              

      

      

      
        	
                Date:
      April
      7, 2009

              	
                Date:
      April
      17, 2009

              
	
                /s/
      John Lanzafame

              	
                /s/
      Andreas Melzer

              
	
                Biophan
      Technologies Inc. (John Lanzafame)

              	
                Biophan
      Europe GmbH (Andreas Melzer)

              

      

      

      
        	
                Date:
      April
      4, 2009

              	
                Date:
      April
      17, 2009

              
	
                /s/
      Michael Friebe

              	
                /s/
      Andres Melzer

              
	
                Tomovation
      GmbH (Michael Friebe)

              	
                Andreas
      Melzer

              

      

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      3

       

      Shareholders ́
resolution of Biophan Europe GmbH

      

      The
shareholders of Biophan Europe GmbH waive their right to convene a shareholders ́
meeting and agree to the above mentioned settlement agreement.

      

      Signed by
shareholders of Biophan Europe GmbH:

      

        
          
            	
                    Date:
      April
      7, 2009

                  
	
                    /s/
      John Lanzafame

                  
	
                    Biophan
      Technologies Inc. (John
Lanzafame)

                  

          

        

      

      

      
        
          	
                  Date:
      April
      4, 2009

                	
                  Date:
      April
      17, 2009

                
	
                  /s/
      Michael Friebe

                	
                  /s/
      Andres Melzer

                
	
                  Tomovation
      GmbH (Michael Friebe)

                	
                  Andreas
      Melzer

                

        

      

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      4

       

      Settlement
agreement between Biophan Technologies Inc. and aMRIs Patente VerwaltungsGmbH
& Co. KG (AMP), AMRIS Patente GmbH (AMRIS), Tomovation GmbH and Michael
Friebe

      

      In order
to settle all disputes and claims between the parties, the parties herewith
agree as follows without acknowledging any legal obligation
thereto:

      

      
        	
                1.

              	
                Michael
      Friebe agrees to sell his shares in aMRIs Patente VerwaltungsGmbH &
      Co. KG for a sum of EUR 70.000,00 to Andreas
  Melzer.

              

      

      

      
        	
                2.

              	
                Tomovation
      agrees to sell its shares in AMRIS Patente GmbH for a sum
      of  EUR 12.700,00 to Andreas Melzer. The provision in this
      clause is conditional to the execution of a formal notarized
      agreement.

              

      

      

      
        	
                3.

              	
                The
      parties agree to merge the two entities, Biophan Europe and aMRIs Patente
      VerwaltungsGmbH & Co. KG (AMP) into a Newco in order to consolidate
      the operating entity with the patent holding entity. Andreas Melzer as CEO
      of AMP is herewith authorized to take all necessary steps to prepare the
      merger. The provision in this clause is conditional to the execution of
      the formal notarized merger
agreements.

              

      

      

      
        	
                4.

              	
                On
      the date hereof Biophan Inc. and AMP have signed an Addendum No 2 to the
      AMP-Biophan License Agreement of February 24, 2005 whereby Biophan Inc’s
      rights are terminated with the exception of the rights sublicensed to
      Boston Scientific Scimed (BSS), thereby returning the VCF-patent license
      and other rights to AMP and all claims between Biophan Inc. and AMP are
      settled.

              

      

      

      
        	
                5.

              	
                Subject
      to the valid execution and fulfillment of the share purchase agreements
      referred to in items 1. and 2. above and of the license termination
      agreement between Stefan Hellwig, Michael Friebe and Biophan Europe GmbH,
      AMP and AMRIS on the one hand and Michael Friebe on the other hand
      mutually release all claims between each other as accumulated or asserted
      per today.  If this mutual release constitutes a waiver of
      claims the parties herewith agree to any such
  waiver.

              

      

      

      
        	
                6.

              	
                The
      parties agree that this Settlement Agreement and the previous Settlement
      Agreement between Biophan Technologies Inc., Biophan Europe GmbH,
      Tomovation GmbH and Andreas Melzer shall simultaneously become valid and
      binding upon the respective parties upon
  signing.

              

      

      

      
        	
                7.

              	
                This
      Settlement Agreement supersedes and replaces all previous settlement
      agreements between the parties relating to the subject matter of this
      Settlement Agreement.

              

      

      

      
        
          
            
              
                
                  
                    
                      
                        	Date:
      April
      7, 2009	
                                Date:
      April
      17, 2009

                              
	/s/
      John Lanzafame	
                                /s/
      Andreas Melzer

                              
	Biophan
      Technologies Inc. (John Lanzafame)	
                                aMRIs
      Patente VerwaltungsGmbH & Co.

                                KG
      (AMP) (Andreas
Melzer)

                              

                      

                    

                  

                

              

            

          

        

      

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      5

       

      
        
          	
                  Date: April
      4, 2009

                	
                  Date:
      April
      4, 2009

                
	
                  /s/
      Michael Friebe

                	
                  /s/
      Michael Friebe

                
	
                  Tomovation
      GmbH (Michael Friebe)

                	
                  Michael
      Friebe

                

        

      

       

      
        	
                Date:
      April
      14, 2009

              
	
                /s/
      Andreas Melzer

              
	
                AMRIS
      Patente GmbH

              
	
                (Andreas
      Melzer)

              

      

      

      Shareholders ́
resolution of aMRIs Patente VerwaltungsGmbH & Co. KG

      

      The
shareholders of aMRIs Patente VerwaltungsGmbH & Co. KG waive their right to
convene a shareholders ́ meeting and agree to the above mentioned settlement
agreement.

      

      Signed by the shareholders of
AMP:

      

      
        
          
            	
                    Date:
      April
      4, 2009

                  	
                    Date: April
      17, 2009

                  
	
                    /s/
      Michael Friebe

                  	
                    /s/
      Andreas Melzer

                  
	
                    Michael
      Friebe

                  	
                    Andreas
      Melzer

                  

          

        

      

      

      
        
          	
                  Date:
      April
      17, 2009

                
	
                  /s/
      Andrea Melzer

                
	
                  AMRIS
      Patente GmbH (Andreas Melzer)

                

        

      

      

      Shareholders ́
resolution of AMRIS Patente GmbH

      

      The
shareholders of AMRIS Patente GmbH waive their right to
convene a shareholders ́ meeting and agree to the above mentioned settlement
agreement.

      

      Signed by the shareholders of AMRIS
Patente GmbH:

      

      
        
          	
                  Date:
      April
      4, 2009

                	
                  Date:
      April
      17, 2009

                
	
                  /s/
      Michael Friebe

                	
                  /s/Andrea
      Melzer

                
	
                  Tomovation
      GmbH (Michael Friebe)

                	
                  Andreas
      MelzerUnassociated Document

    

      Agreement
of Mutual Releases and Waivers

      with
respect to the

      Share
Purchase Agreement

      between
Biophan Inc.– aMRIs GmbH (now Biophan Europe) and others

      of
February 24, 2005 (the “Share Purchase Agreement”).

      

      This is an Agreement of Mutual
Releases and Waivers, dated _________________, 2009, among Biophan
Europe, GmbH (“Biophan Europe”), formerly known as aMRIs GmbH, having a mailing
address of Niederseelbacherstrasse 66, 66527 Niedernhausen, Biophan
Technologies, Inc. (“Biophan Inc.”), having a mailing address of 15 Schoen
Place, 14534 Pittsford, NY, USA, Tomovation GmbH (“Tomovation”), having a
mailing address of Behringhauser Str. 31, 44575 Castrop-Rauxel, and Prof. Dr.
Andreas Melzer (“Melzer”), having a mailing address of Niederseelbacherstrasse
66, 66527 Niedernhausen. Biophan Inc., Biophan Europe, Tomovation and Melzer are
collectively called the “Parties” and each may be referred to as a
“Party.”

      

      Background. The Parties
entered into the Share Purchase Agreement and the Capital Pledge Agreement
on February 24, 2005. Under the Capital Pledge Agreement, Biophan Inc. pledged
certain Biophan Europe shares as collateral for its performance of certain
capitalization obligations under Sections 1.4(a) and (b) of the Share Purchase
agreement. The Parties are restructuring the relationship between Biophan Inc.
and Biophan Europe. In consideration of the Parties’ entry into and performance
of the Settlement Agreement between Biophan Inc., Biophan Europe GmbH,
Tomovation and Andreas Melzer, the Settlement Agreement between Biophan Inc.,
aMRIs Patente Verwaltungs GmbH & Co. KG, AMRIS Patente GmbH (AMRIS)
Tomovation and Michael Friebe  and the Addendum No. 2 to and
Ratification of the AMP-Biophan License Agreement on this date (together, the
“Settlement Agreements”), the Parties are willing to release certain claims and
causes of action and waive certain rights under the Share Purchase Agreement and to terminate the Capital
Pledge Agreement.

      

      Now, therefore, in
consideration of the premises and intending to be legally bound, the Parties
acknowledge and agree as follows:

      

      
        	
                1.

              	
                Subject
      to the fulfillment of all obligations due by Tomovation under the
      Settlement Agreements and the transfers of shares and participation
      interests stipulated therein due by Tomovation, Biophan Inc. and Biophan
      Europe each releases all claims, demands and causes of action under or
      related to the Share Purchase Agreement that it does or may have or
      may have had at any time in the past, present or future, whether known or
      unknown, vested or conditional, against Tomovation or any of its officers,
      directors, shareholders or
employees

              

      

      

      
        	
                2.

              	
                Subject
      to the fulfillment of all obligations by Biophan Inc. due to Tomovation
      under the Settlement Agreement, Tomovation releases all claims, demands
      and causes of action under or related to the Share Purchase Agreement that it does or may have or
      may have had at any time in the past, present or future, whether known or
      unknown, vested or conditional, against Biophan Inc. or Biophan Europe or
      any of their officers, directors, shareholders or
    employees.

              

      

      
        
           

        

        
           

          
            

          

        

        
           

        

      
2

      

      
        	
                3.

              	
                Subject
      to the fulfillment of the payment obligations due by Biophan Inc. to
      Biophan Europe under the Settlement Agreements, Biophan Inc. and Biophan
      Europe each releases all claims, demands and causes of action under or
      related to the Share Purchase Agreement that it does or may have or
      may have had at any time in the past, present or future, whether known or
      unknown, vested or conditional, against the other or any of its officers,
      directors, shareholders or
employees.

              

      

      

      
        	
                4.

              	
                Subject
      to the transfers of shares and participation interests stipulated in the
      Settlement Agreements due by Biophan Inc. to Andreas Melzer, Biophan Inc.
      and Andreas Melzer each releases all claims, demands and causes of action
      under or related to the Share
      Purchase Agreement that
      it does or may have or may have had at any time, whether known or unknown,
      vested or conditional, against the other or any of its officers,
      directors, shareholders or
employees.

              

      

      

      
        	
                5.

              	
                The
      Parties agree that, with the fulfillment of Biophan Inc. ́s obligations
      under the Settlement Agreements, Biophan Inc. has performed all of its
      obligations under Section 1.4 of the Share Purchase Agreement
      and:

              

      

      

      
        	
                 
      

              	
                a.

              	
                all
      shares pledged under the Capital Pledge Agreement are and shall be
      released to Biophan Inc. and that each of them will take all necessary
      steps to deliver the shares to Biophan
Inc.;

              

      

      
        	
                 
      

              	
                b.

              	
                Biophan
      Inc. has no further obligations with respect to Section 1.4 of the Share
      Purchase Agreement.

              

      

      

      
        	
                6.

              	
                This
      Agreement and the rights and obligations of the Parties hereunder shall be
      governed by New York law, without regard to conflict of laws
      principles.

              

      

      

      
        	
                7.

              	
                Each
      of the Parties consents to the jurisdiction of the Federal courts in New
      York to hear any dispute under or related to this Agreement. Each of the
      Parties hereby designates the address set forth above as its address for
      purposes of service of process.

              

      

      

      
        	
                8.

              	
                This
      Agreement shall be binding on the Parties and their respective successors,
      assigns and personal
representatives.

              

      

      
        
           

        

        
           

          
            

          

        

        
           

        

      
3

      

      
        	
                9.

              	
                This
      Agreement, the Share Purchase Agreement, the Capital Pledge Agreement and
      the Settlement Agreements constitute the entire agreement among the
      Parties related to the Share Purchase Agreement and there are no other
      agreements related to the Share Purchase Agreement written or oral,
      express or implied.

              

      

      

      In witness whereof, the
Parties have executed this Agreement of Mutual Release and Waiver by their duly
authorized representatives.

      

      Tomovation GmbH

       

      By: /s/ Michael
Friebe

      Name: Dr. Michael Friebe

      Title: Chief Executive Officer

       

      Biophan
Technologies, Inc.

       

      By: /s/
John Lanzafame

      Name:
John Lanzafame

      Title:
Chief Executive Officer

       

      Biophan
Europe GmbH.

       

      By: /s/
Andreas Melzer

      Name:
Prof. Dr. Andreas Melzer

      Title:
Chief Executive Officer

       

      Prof.
Dr. Andreas Melzer

       

      /s/
Andreas Melzer

       

      Prof. Dr.
Andreas Melzer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}]]